TY  - JOUR
AB  - Summary: Background: Glargine U300 (Gla-300) is a further development of glargine U100 (Gla-100). Since 2015, Gla-300 has been available in Germany and Austria. We compared patients initiating therapy with Gla-300 with patients starting with Gla-100. Moreover, it was investigated whether patients from real-life diabetes care differ from patients participating in the EDITION clinical study program. Summary: Methods: Data are based on the diabetes registries DPV and DIVE. Patients started/switched to Gla-100 or Gla-300 in 2015 were included. Linear regression was applied for bodyweight (BW), BMI, HbA 1C , daily total and basal insulin dose/kgBW and negative binomial regression for severe hypoglycemia. Data were adjusted for age, sex, and diabetes duration. Summary: Results: 14,123 patients were identified (Gla-100: 11,397; Gla-300: 2726). Gla-300 patients with T1D were older, T2D patients younger compared to subjects using Gla-100 (both p < 0.0001). In Gla-300 subjects, diabetes duration was longer (both p < 0.0001). Patients started/switched to Gla-300 had a higher BW, a higher BMI and a lower baseline HbA 1C . The rate of severe hypoglycemia was comparable. Total and basal insulin doses/kgBW were higher in patients with Gla-300. Summary: DPV/DIVE subjects were older, had a lower BW, and were more frequently male compared to EDITION patients. HbA 1C was higher in T1D patients from DPV/DIVE. Summary: Conclusion: Data from the diabetes registries DPV/DIVE indicate differences between Gla-300 and Gla-100 patients at the onset of insulin therapy. This analysis provides additional information to the EDITION clinical study program.
AU  - Bohn, B.*
AU  - Bramlage, P.*
AU  - Wagner, C.*
AU  - Kaltheuner, M.*
AU  - Welp, R.*
AU  - Sziegoleit, S.*
AU  - Zimmermann, A.*
AU  - Reuter, H.M.*
AU  - Hummel, M.
AU  - Gloyer, J.*
AU  - Holl, R.W.*
AU  - Danne, T.*
C1  - 51779
C2  - 43489
SP  - 415–422
TI  - Welche Patienten aus der Routinebetreuung verwenden das neue Insulin-Analogon Glargin U300 im Vergleich zu Patienten mit Glargin U100? Eine multizentrische Analyse von 14.123 Patienten mit Insulin Glargin aus den Diabetesregistern DPV und DIVE.  
JO  - Wien. Med. Wochenschr.
VL  - 168
IS  - 15-16
PY  - 2018
SN  - 0724-7176
ER  - 

TY  - JOUR
AU  - Kaplanian, M.*
AU  - Hackl, M.T.*
AU  - Stemmer, K.
AU  - Luger, A.*
AU  - Scherer, T.*
AU  - Fuernsinn, C.*
C1  - 54686
C2  - 45761
CY  - Sachsenplatz 4-6, Po Box 89, A-1201 Wien, Austria
SP  - 348-348
TI  - Posture of adipose Mice under hypoxia reduces Hyperglycemia without Improving Insulin Sensitivity.
JO  - Wien. Med. Wochenschr.
VL  - 130
PB  - Springer Wien
PY  - 2018
SN  - 0724-7176
ER  - 

TY  - JOUR
AU  - Lassi, M.
AU  - Gerlini, R.
AU  - Darr, J.
AU  - Teperino, R.
C1  - 54687
C2  - 45762
CY  - Sachsenplatz 4-6, Po Box 89, A-1201 Wien, Austria
SP  - 353-354
TI  - Paternal circadian arrhythmia affects offspring health and feeding behaviour.
JO  - Wien. Med. Wochenschr.
VL  - 130
PB  - Springer Wien
PY  - 2018
SN  - 0724-7176
ER  -